Our data identify NF-κB as a transcriptional driver in TKI resistance, and implicate PSMD1 and PSMD3 as plausible therapeutic targets worthy of future investigation in CML and possibly other malignancies. The gene discussed is NFKB1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.